Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

For a patient who would benefit from an anabolic agent for osteoporosis, do you prefer romosuzumab over teriparatide in the absence of contraindications to either agent?

3
3 Answers

Mednet Member
Mednet Member
Rheumatology · U of AZ Phoenix Dept of Orthopaedics

Both teriparatide and romozosumab are excellent drugs to treat osteoporosis with documented risk reduction in fractures. TPTD reduces spine fracture about 85% and romozosumab about 75%. Both are excellent. They have very different biologies with TPTD being a remodeling-based anabolic and romozosumab...

What is your approach to patients with PMR on steroids over a prolonged initial course who start to experience weakness concerning for steroid myopathy?

2
1 Answers

Mednet Member
Mednet Member
Rheumatology · Berkshire Health Systems

One of two approaches, similar to the case in inflammatory myopathy: either increase steroid dose (pain/weakness increase argues for steroid myopathy; decrease means there is need for higher dose/longer taper) or decrease steroid dose (increase in symptoms means there is need for more/longer steroid...

How would you approach a young patient with a history of APLS and VTE, desiring hormone replacement therapy after oophorectomy?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · UT Southwestern Medical Center

I think the answer is not straightforward. What APLAs are positive and what was/is the titer? Were there other risk factors at the time of the clot (smoking, oral contraceptives, etc...) My general recommendation would be to avoid estrogens in patients with APLAs. I can imagine a scenario where the ...

Would you feel comfortable combining MMF and an IL-17 blocker in a patient with both limited scleroderma and psoriatic arthritis?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Ohio State University

We combine medications all the time! So the question is what is the risk-benefit? How bad psoriatic arthritis? Otezla and orencia for scleroderma? Otezla and MMF? Why not IL-23? Vs IL-17? Why not just methotrexate? So many choices you have! Also, you can always start with both for 2-6months then w...

How would you approach a patient with incidentally noted infrarenal periaortitis with positive C-ANCA, normal inflammatory markers and no systemic symptoms?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Director, Vasculitis Clinical Research Consortium

Based on data we and others have published over the past 20 years, the specificity of testing for ANCA depends on testing for antibodies to the specific antigens proteinase 3 (PR3) and myeloperoxidase (MPO) by ELISA or other newer methods. Immunofluorescence (IF) testing alone for ANCA is not accept...

How do you approach low to moderate titer of APLS when working up unprovoked DVT if it is persistent on repeat testing?

4
4 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh

I have a low threshold to recommend long term (indefinite) anticoagulation for unprovoked thrombosis, regardless of whether there is positive APLS testing. I do agree with Dr. @Dr. First Last, however, that shared decision-making is important when committing a patient to prolonged anticoagulation, a...

What is your approach to managing RA patients with history of organ transplant already on immunosuppressive therapy such as cyclosporine or cellcept?

3
4 Answers

Mednet Member
Mednet Member
Rheumatology · Institute for Rheumatic & Autoimmune Diseases, Atlantic Health System

In contrast to my esteemed colleague, @Dr. First Last, in 38+ years in clinical rheumatology practice (maybe those 3 years make a difference), I have seen RA occur in 3 patients with solid organ transplants. All 3 were renal transplants; all 3 were recurrent diseases that had been previously control...

How would you manage immune check point inhibitor induced capillary leak syndrome refractory to IVIG monotherapy?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Ohio State University

There is no great evidence and only case reports. Diuretics and supportive management. Stopping the ICIs is likely essential at this point because we do not know how to safely rechallenge yet. There is a discussion of possible using anti IL-6 therapy for capillary leak if IVIG and corticosteroids do...

How do you approach the workup for a patient with persistently elevated inflammatory markers (CRP and ESR) whose history and exam do not point to a clear cause?

7
4 Answers

Mednet Member
Mednet Member
Rheumatology · Berkshire Health Systems

Our hematologist/oncologist referred just such a patient. No evidence of malignancy, but elevated CRP &ESR. I did an “internist’s” workup as I would for dermatomyositis, starting with the most important and therefore most thorough aspect: taking a full and very “invasive” history, followed by a comp...

What is your approach to the diagnosis and management of lupus cystitis?

2 Answers

Mednet Member
Mednet Member
Rheumatology · MUSC Health

Lupus cystitis is a rare complication of lupus but there does appear to be an association. I depend on the urologist to confirm the diagnosis of interstitial cystitis. If mild to moderate in activity, will use standard treatments for cystitis with bladder infusions, bladder relaxants in collaboratio...